TransCode Therapeutics, Inc. (RNAZ) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Track TransCode Therapeutics, Inc. (RNAZ) stock performance with short-term forecasts for 2025 and long-term RNAZ price prediction till 2050. Review historical trends, get analyst Buy/Sell/Hold ratings, and stay updated with the latest TransCode Therapeutics, Inc. headlines.
1 Month Prediction
$1.00 [-27.53%]
3 Month Prediction
$1.00 [-27.53%]
6 Month Prediction
$1.00 [-27.53%]
1 Year Prediction
$1.00 [-27.53%]
3 Year Prediction
$1.00 [-27.53%]
5 Year Prediction
$1.00 [-27.53%]
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc is a clinical-stage biopharmaceutical company that develops RNA-based therapeutics and diagnostics for cancer treatment. Their main candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), which is a master regulator of metastatic cell viability in various cancers, including breast, pancreatic, ovarian, colon cancer, and glioblastomas.
The company was founded in 2016, and is headquartered in Boston, Massachusetts.
TransCode Therapeutics, Inc. (RNAZ) Historical Performance
IPO Date
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) went public on 09 July, 2021.
Change
Since inception, RNAZ has fallen from $76824.00 to $1.38, a massive -100.0% decrease since 2021.
Historical Highs and Lows
In the past 4 years, the stock reached a high of $80256.00 and a low of $1.38.
52 Week Range
$0.645
$66.33
The current price $1.36 is not near the 52-week extremes, which means that the stock is neither overbought nor underbought.
RNAZ Stock Price History
Based on RNAZ stock's historical price data, this table shows how the stock has performed in the last 4 years. Since 2021, the RNAZ stock has fallen from $10560.0 - $76032.0 to $1.38 - $7.56, which is down -100.0%. Currently, the stock follows downward trend.
Here, we have calculated stock range of RNAZ, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2022 | $10560.0 - $76032.0 | $40931.0 | -45.47 | 1 Year Change |
| 2023 | $217.8 - $19826.4 | $5497.14 | -92.68 | 2 Year Change |
| 2024 | $3.37 - $58.58 | $20.61 | -99.97 | 3 Year Change |
| 2025 | $1.38 - $7.56 | $3.64 | -100.0 | 4 Year Change |
RNAZ Price Performance
6-Month Performance
RNAZ stock dropped by 91.01% in the last six months.
1-Year Performance
The stock has trended downwards by 93.11% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 100.00%.
According to TransCode Therapeutics, Inc.'s historical data, below graph gives us the exact picture of how the RNAZ stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 0 year and a decline in 3 years.
2022
73.50% ↓
2023
98.77% ↓
2024
98.45% ↓
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
TransCode Therapeutics, Inc. (RNAZ) Financials & Stock Analysis
Market Capitalization
TransCode Therapeutics, Inc. has a market capitalization of $946.90K, which places RNAZ in the nano-cap category.
Fundamental Analysis
EPS: $-0.16 (Q3), $-103.61 (1Y)
EPS decreased 78.38% since last quarter, and decreased 90.43% since last year.
Net Income: $-2.32 M (Q3), $-18.55 M (1Y)
Net Income decreased 55.28% since last quarter, and increased 5.59% since last year.
Free Cash Flow: $-3.93 M (Q3), $-18.11 M (1Y)
Free Cash Flow increased N/A since last quarter, and increased 14.16% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for RNAZ stock. These indicators help you understand TransCode Therapeutics, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for RNAZ stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $1.87 |
| SMA50 | $5.14 |
| SMA200 | $13.57 |
| RSI | 35.98 |
| Beta | 1.15 |
SMA20 > Current Price
This signals RNAZ stock is in short-term bearish momentum.
SMA50 > Current Price
This signals RNAZ stock is in mid-term bearish momentum.
SMA200 > Current Price
This signals RNAZ stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for RNAZ stock is Bearish. Out of all indicators, 2 indicates bullish signals, 4 signals bearish trends and 3 gives neutral trends. The RNAZ stock forecast was last updated on 21 March, 2025.
TransCode Therapeutics, Inc. (RNAZ) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to fall to $1.00 by the end of 2025, and can reach around $0.91 to $0.51 in 2026. And, the long-term forecast suggests that the stock may further jump to $0.76 - $1.82 in 2028, and $0.99 - $1.89 by 2031. So, the RNAZ stock shows a strong downward trend in the next several years.
Short-term RNAZ Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-04 | $1.00 | -27.53% |
| 2025-05 | $1.00 | -27.53% |
| 2025-06 | $1.00 | -27.53% |
| 2025-07 | $1.00 | -27.53% |
| 2025-08 | $1.00 | -27.53% |
| 2025-09 | $1.00 | -27.53% |
| 2025-10 | $1.00 | -27.53% |
| 2025-11 | $1.00 | -27.53% |
| 2025-12 | $1.00 | -27.53% |
In 2025, the RNAZ stock price is expected to fluctuate between $1.0 and $1.0. According to the monthly forecast, the stock could drop to $1.00 by December 2024. If compared to the RNAZ's current price, the stock could lose -27.53% by the end of this year.
Long-term RNAZ Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $0.91 | $0.81 | $0.51 | -63.04% |
| 2027 | $1.71 | $2.38 | $0.06 | -95.65% |
| 2028 | $0.76 | $0.32 | $1.82 | 31.89% |
| 2029 | $0.20 | $1.10 | $0.40 | -71.01% |
| 2030 | $1.57 | $1.24 | $0.40 | -71.01% |
| 2031 | $0.99 | $0.37 | $1.89 | 36.97% |
| 2032 | $0.94 | $1.00 | $1.46 | 5.8% |
| 2033 | $1.24 | $1.00 | $1.27 | -7.96% |
| 2034 | $0.48 | $2.38 | $0.51 | -63.04% |
| 2035 | $0.65 | $2.04 | $1.22 | -11.59% |
| 2036 | $0.89 | $1.13 | $0.97 | -29.71% |
| 2037 | $0.53 | $1.48 | $0.07 | -94.93% |
| 2038 | $0.43 | $0.11 | $1.64 | 18.85% |
| 2039 | $1.14 | $2.37 | $1.57 | 13.78% |
| 2040 | $0.29 | $1.00 | $1.22 | -11.59% |
| 2041 | $1.37 | $0.60 | $1.92 | 39.14% |
| 2042 | $1.16 | $-0.38 | $0.96 | -30.43% |
| 2043 | $1.74 | $1.34 | $1.35 | -2.17% |
| 2044 | $1.29 | $1.21 | $1.71 | 23.92% |
| 2045 | $0.39 | $2.09 | $0.26 | -81.16% |
| 2046 | $-0.06 | $-0.08 | $1.57 | 13.78% |
| 2047 | $1.44 | $-1.48 | $1.36 | -1.44% |
| 2048 | $0.81 | $1.35 | $1.54 | 11.6% |
| 2049 | $-0.40 | $1.02 | $0.46 | -66.66% |
| 2050 | $0.72 | $1.43 | $0.02 | -98.55% |
| 2051 | $1.59 | $0.99 | $1.56 | 13.05% |
TransCode Therapeutics, Inc. (RNAZ) Stock Price Prediction & Forecast 2025
At the start of 2025, the RNAZ stock was at $7.56. Today, it is trading at $1.38, which is -81.75% decrease from price at the beginning of the year. By the end of this year, you can expect the stock to fall to $1.00 by December 2025 with a -27.53% change.
TransCode Therapeutics, Inc. (RNAZ) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant depreciation in the RNAZ stock. During this period, the RNAZ's price is forecasted to shift from $0.91 to $0.40, which is -56.04% loss.
In 2026, the stock would possibly open at $0.91, descends to $0.81 by mid-year, and wraps up at $0.51, reflecting a decrease from today's price. Further moving to 2030, the stock can kick off the year at $1.57, drop to $1.24 by mid-year, and finish at $0.40, which is -71.19% change from current price.
TransCode Therapeutics, Inc. (RNAZ) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $0.99 to $1.22, which is up 37.04%
In 2031, we can expect RNAZ to fluctuate between $0.99 and $1.89, a shift indicating a 37.04% gain by year-end compared to current price. And Until 2040, RNAZ can likely vary from $0.29 to $1.22. By the end of 2040, the stock could record a -11.44% fall from today's stock price.
TransCode Therapeutics, Inc. (RNAZ) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the RNAZ stock can see an a downturn from $1.37 to $0.02 in this period. In 2041, the stock can experience a low of $0.60 by mid-year, closing the year at $1.92. This results in a -56.79% decrease from today.
Moving towards the end of 2050, RNAZ is projected to open the year at $0.72. The stock may peak to $1.43 during mid-year and finish the year at $0.02. Compared to the stock's current price, this translates to an overall loss of -98.28% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
RNAZ Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| GLTO | Galecto, Inc. | - | $6.65 | 51.83% ▲ | $32.48 ▲ |
| CRVO | CervoMed Inc. | - | $6.91 | 208.48% ▲ | $257.27 ▲ |
| SYRS | Syros Pharmaceuticals, Inc. | - | $0.14 | -4.90% ▼ | $3861.03 ▲ |
| ARVN | Arvinas, Inc. | - | $8.30 | -53.11% ▼ | $409.53 ▲ |
| TNYA | Tenaya Therapeutics, Inc. | - | $0.46 | -54.95% ▼ | $790.53 ▲ |
Last updated Mar 21 at 4:22 PM
RNAZ : Buy, Sell Or Hold?
Analyst Ratings
Based on 1 analysts, 1 rated as a strong buy, 0 recommended a buy, 0 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.So, according to analyst ratings, the recommendation for RNAZ stock is Buy.
Expert Analysis
According to RNAZ short-term and long-term forecast, TransCode Therapeutics, Inc. shares are projected to go down by 98.55%, and reach a value of $0.02 per share by 2050.
As per technical analysis, indicators show a Bearish sentiment, while Fear & Greed Index stands at 35.714285714285715, which signals Fear. Also, RNAZ has recorded 5/30 green days, which reflects a 21.73913043478261% positivity rate with a price volatility of 0.20%.
Plus, Price-to-Earnings (P/E) ratio of 0.0002440898 suggests that RNAZ stock is overvalued. So, Based on RNAZ prediction and analysis, it may be the best time to sell RNAZ stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "RNAZ” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.